TPST$0.4733+0.28%
Tempest Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$7.99M
Float & O/S:
Inst Own:
DilutionScan read 45 of Tempest Therapeutics, Inc.'s SEC filings and found 14 warrant series, 2 ATM programs, 1 equity line, 5 shelf registrations, 1 S-1 registration and 5 completed offerings on file for TPST. The latest dilution event on file is a registration statement on Oct 1, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
TPST
Going-concern warning, cash nearly gone
Snapshot
Tempest is a clinical-stage cancer and cell-therapy biotech with no revenue, losing $26.3M in FY 2025 and burning through cash.
What's Happening Right Now
- : A special stockholder meeting to remove supermajority voting requirements was adjourned to August 17, 2026 after insufficient votes were cast to approve the charter change.
- : Q2 2026 net loss was $5.2M, cash fell to just $0.8M from $7.7M at year-end, but the company reported a 100% complete response rate across 15 patients in an early CAR-T trial and named new board members and a business development lead.
- : Tempest partnered with Senlang Biotechnology to co-develop TPST-4003, a CD7-targeted in vivo CAR-T candidate, starting with a small investigator-led trial in China for autoimmune disease patients.
- : A prospectus filing tied to warrant resales disclosed that the company's auditors have raised substantial doubt about its ability to continue as a going concern.
- : Stockholders approved issuing up to roughly 4.2 million new shares tied to warrant exercises under Nasdaq rules.
